Looking at this filing, it is an S-1 registration statement. Let me assess the substantive disclosure content for the word count gate. The filing contains substantive prospectus content describing the offering structure, securities being registered, warrant tranches, pricing, and terms. This is well over 150 words of substantive content. Now let me check for the exchange and ticker. The filing states the common stock trades on "the Nasdaq Capital Market ('Nasdaq')" but I need to find the ticker symbol as stated in the filing. The filing does not explicitly state a ticker symbol in the text provided. The reference ticker is NASDAQ:IMNN. However, the filing refers to "Nasdaq" and the company is Imunon, Inc., but I cannot confirm the ticker symbol from the filing text itself. I will not state a ticker not confirmed in the filing text. Actually, reviewing more carefully: the filing text does not include a registered-securities table with the ticker. I should omit the ticker rather than guess.

Imunon, Inc. filed an S-1 registration statement in October 2026 seeking to offer up to 20,000,000 shares of common stock together with multiple tranches of common warrants covering up to an additional 70,000,000 shares, on a best-efforts basis.

Key Highlights

  • Offering size: Up to 20,000,000 shares of common stock, or pre-funded warrants in lieu thereof, at an assumed public offering price of $1.25 per share, which was the closing price on October 23, 2026.
  • Total warrant coverage: 350% aggregate warrant coverage across four tranches (Tranche A at 50%, Tranche B at 100%, Tranche C at 100%, and Tranche D at 100% of shares sold).
  • Warrant exercise prices: Assumed exercise prices of $1.25, $1.38, $1.56, and $2.50 per share for Tranche A, B, C, and D common warrants, respectively, equal to 100%, 110%, 125%, and 200% of the assumed combined public offering price.
  • Maximum shares issuable: Up to 91,000,000 shares of common stock issuable upon exercise of all common warrants, pre-funded warrants, exchange warrants, and placement agent warrants combined.
  • Placement agent warrants: Placement agent warrants to purchase up to 1,000,000 shares of common stock are included in the offering structure.
  • Company status: Imunon, Inc. is classified as a non-accelerated filer and a smaller reporting company, according to the filing.

Imunon's Multi-Tranche Warrant Structure and Offering Terms

According to the registration statement, Imunon, Inc., a Delaware corporation headquartered at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648, is offering up to 20,000,000 shares of its common stock (par value $0.01 per share) on a best-efforts basis. The assumed public offering price of $1.25 per share was stated to be the closing price of the company's common stock on the Nasdaq Capital Market on October 23, 2026. Pre-funded warrants may be substituted for shares of common stock in the offering.

The filing discloses a layered warrant structure. Each share sold (or pre-funded warrant in lieu thereof) is accompanied by four warrant tranches: a Tranche A common warrant to purchase one-half of one share of common stock, and Tranche B, C, and D common warrants each to purchase one share of common stock. The assumed exercise prices for these tranches are $1.25, $1.38, $1.56, and $2.50 per share, respectively, representing 100%, 110%, 125%, and 200% of the assumed combined public offering price. The filing states this results in total warrant coverage of 350% of shares sold.

The filing describes exercisability conditions tied to stockholder approval. According to the registration statement, the common warrants "will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the common warrants," unless the offering qualifies as a public offering or the defined "Pricing Conditions" are met, in which case stockholder approval will not be required. The filing also notes that purchasers whose exercise of common warrants would cause them to beneficially own more than 4.99% of outstanding common stock will instead receive exchange warrants, which have identical terms to the pre-funded warrants. The Tranche A common warrants expire on the earlier of the five-year anniversary of the initial exercise date or 30 trading days following that date, according to the partial terms disclosed.

What Was Disclosed

Imunon, Inc. filed an S-1 registration statement disclosing a proposed best-efforts offering of up to 20,000,000 shares of common stock with accompanying four-tranche common warrants, pre-funded warrants, and placement agent warrants, covering a maximum of 91,000,000 underlying shares in total.